- Home
- CE vs LEGN Comparison
CE vs LEGN Comparison
Compare CE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CE
- LEGN
- Stock Information
- Founded
- CE 1918
- LEGN 2014
- Country
- CE United States
- LEGN United States
- Employees
- CE N/A
- LEGN N/A
- Industry
- CE Major Chemicals
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CE Industrials
- LEGN Health Care
- Exchange
- CE Nasdaq
- LEGN Nasdaq
- Market Cap
- CE 8.3B
- LEGN 9.1B
- IPO Year
- CE 2005
- LEGN 2020
- Fundamental
- Price
- CE $73.77
- LEGN $38.19
- Analyst Decision
- CE Hold
- LEGN Strong Buy
- Analyst Count
- CE 16
- LEGN 13
- Target Price
- CE $116.33
- LEGN $81.46
- AVG Volume (30 Days)
- CE 2.4M
- LEGN 1.6M
- Earning Date
- CE 11-04-2024
- LEGN 11-12-2024
- Dividend Yield
- CE 3.79%
- LEGN N/A
- EPS Growth
- CE N/A
- LEGN N/A
- EPS
- CE 9.95
- LEGN N/A
- Revenue
- CE $10,479,000,000.00
- LEGN $520,183,000.00
- Revenue This Year
- CE N/A
- LEGN $110.04
- Revenue Next Year
- CE $2.67
- LEGN $77.16
- P/E Ratio
- CE $7.35
- LEGN N/A
- Revenue Growth
- CE N/A
- LEGN 122.96
- 52 Week Low
- CE $72.78
- LEGN $38.02
- 52 Week High
- CE $172.16
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- CE 11.20
- LEGN 29.40
- Support Level
- CE $90.51
- LEGN $38.94
- Resistance Level
- CE $129.07
- LEGN $41.87
- Average True Range (ATR)
- CE 3.53
- LEGN 2.20
- MACD
- CE -4.13
- LEGN -0.30
- Stochastic Oscillator
- CE 1.76
- LEGN 1.74
About CE Celanese Corporation
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.